Ascendis Pharma A/S R&D Update Transcript
/- -
Welcome, everyone, to Ascendis Pharma's Virtual R&D Program Update. We are live from sunny Copenhagen here today. I'm Scott Smith, Chief Financial Officer of Ascendis Pharma.
Today, as expected, we'll be making some forward-looking statements. Actual results may differ materially from these statements. Please refer to the associated risk factors on our Form 20-F filed with the SEC and our other SEC filings.
Today, in our action packed agenda, after I finished my very long part here, I will turn it over to Jan, who will give an overview of Ascendis for new investors as well as some opening comments. We have a great agenda running through 3 clinical stage programs -- 3 out of our 5 clinical stage programs. First, in endocrinology rare disease, we have TransCon PTH and TransCon CNP. And then we'll move over to oncology with our first-ever data from TransCon TLR7/8 Agonist. We'll then conclude with a question-and-answer session. (Operator Instructions)
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
